ArticleBMC ophthalmology2018
Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis.
Article in BMC ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Management of Extraocular Retinoblastoma: ICMR Consensus Guidelines.Indian journal of pediatrics · 2024Guideline
- Causality-Guided Machine Learning for Retinoblastoma Survival Prediction: Development and Comparative Evaluation Using SEER.Medical sciences (Basel, Switzerland) · 2026Article
- Orbital Fungating Mass as a Rare Manifestation of Retinoblastoma: A Case Study in Palliative Care.The American journal of case reports · 2026Article
- Investigation of GD2 synthase as a potential marker for retinoblastoma poor prognosis.Molecular biology reports · 2025Article
- Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case report.Frontiers in oncology · 2025Article
- Establishment and validation of a prognostic risk early-warning model for retinoblastoma based on XGBoost.American journal of cancer research · 2025Article
- miR-4529-3p Promotes the Progression of Retinoblastoma by Inhibiting RB1 Expression and Activating the ERK Signaling Pathway.Molecular biotechnology · 2024Article
- Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy.Frontiers in pediatrics · 2024Article
- Oncogenic Proteomics Approaches for Translational Research and HIV-Associated Malignancy Mechanisms.Proteomes · 2023Review
- Piperlongumine inhibits proliferation and oncogenic MYCN expression in chemoresistant metastatic retinoblastoma cells directly and through extracellular vesicles.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Natural History of Untreated Retinoblastoma.Cancers · 2021Article
- Treatment Outcome of Children with Retinoblastoma in a Tertiary Care Referral Hospital in Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- TUG1 promotes retinoblastoma progression by sponging miR-516b-5p to upregulate H6PD expression.Translational cancer research · 2021Article
- Clinical characteristics, treatment and prognosis of children with unilateral retinoblastoma and intracranial segment of Retrobulbar optic nerve invasion.BMC ophthalmology · 2021Article
- Long-Term Clinical Results and Management following Vitrectomy in Undetected Retinoblastoma Eyes.Ocular oncology and pathology · 2020Article
- MiR-486-3p inhibits the proliferation, migration and invasion of retinoblastoma cells by targeting ECM1.Bioscience reports · 2020Article
- Survival and ocular preservation in a long-term cohort of Japanese patients with retinoblastoma.BMC pediatrics · 2020Article
- Metastatic retinoblastoma at presentation: Clinical presentation, treatment, and outcomes.Oman journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundRetinoblastoma is the most common primary intraocular tumor and more and more attention has been paid to the developing countries. This study was aimed to evaluate the clinical features, treatment, and prognosis of retinoblastoma patients with central nervous system (CNS) metastasis in Beijing Tongren Hospital, one of the largest tertiary eye centers in China.
methodsClinical data of 31 consecutive retinoblastoma patients with CNS metastases, who were diagnosed at the Department of Pediatrics in Beijing Tongren Hospital between September 2005 and December 2015, were retrospective analyzed.
resultsThe median age at presentation was 29 months (range from 5 to 108 months). Magnetic resonance imaging (MRI) results indicated that 16 patients (56.6%, 16/31) presented with meningeal involvement, 12 (38.7%, 12/31) presented with intracranial mass, 11 (35.5%, 11/31) presented with thickened optic nerve, and 5 (16.1%, 5/31) presented with concurrent meningeal and spinal cord membrane involvement. Retinoblastoma cells were detected in the cerebrospinal fluid (CSF) of 12 patients (44.4%, 12/27). Laboratory examinations on the blood and CSF were performed for 11 patients who had received six cycles of systemic chemotherapy, indicated that the serum level of neurone-specific enolase (NSE) after chemotherapy was significantly lower than that before chemotherapy (P < 0.05). At the end of the follow-up, 25 patients were dead with a median survival time of 6 months (1 d - 21 months), and 6 cases were alive and continued to receive treatment.
conclusionOur results were basically consistent with previous reports in the developing countries, and it could be guidance for clinical treatment, prognosis and prevention of CNS metastases in retinoblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.